A
Apogee Therapeutics Inc
NASDAQ:APGE
Apogee Therapeutics Inc
NASDAQ:APGE
Price:
73.51
USD
-1.57%
Market Closed
Market Cap:
$5B
Relative Value
The Relative Value of one APGE stock under the Base Case scenario is 2.03 USD. Compared to the current market price of 73.51 USD, Apogee Therapeutics Inc is Overvalued by 97%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
APGE
Relative Value
Base Case
2.03
USD
Overvaluation 97%
A
Multiples Across Competitors
APGE Competitors Multiples
Apogee Therapeutics Inc Competitors
Apogee Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
A
|
Apogee Therapeutics Inc
NASDAQ:APGE
|
5B USD | 0 | -19.7 | -15.2 | -15.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
398.4B USD | 6.5 | 95.2 | 15.6 | 21.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
198.2B USD | 5.4 | 25.7 | 14.8 | 14.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
180.2B USD | 6.1 | 21.2 | 13.2 | 16.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.4B USD | 10.1 | 30.7 | 23.2 | 24.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.9B USD | 5.5 | 17.5 | 13 | 14.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.5B AUD | 3.1 | 34.4 | 11.4 | 14.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
38.3B EUR | 10.7 | 34.4 | 37.3 | 38 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
